BI Gets Down To Business Early With Trio Of Pacts
The German group’s fibro-inflammatory deal with Kyowa Kirin has come in the same week as a new oncology collaboration with partner 3T and a liver disease alliance with China’s Ribo.
You may also be interested in...
Sirius has joined the race to develop China’s first homegrown RNAi therapy and is backing its assets’ potential in chronic cardiovascular disorders, including possible once-yearly dosing, the venture’s CEO tells Scrip in an interview.
Plus deals involving Biocytogen/Radiance, Maruho/AOBiome, LGChem/Rhythm, IASO/Umoja, JW Therapeutics/2seventy and 13 other transactions.
The partners revealed Phase III trial details for GLP-1/glucagon agonist survodutide, where the biggest challenge may be overcoming gastrointestinal side effects seen in Phase II.